The interaction of bortezomib with multidrug transporters: implications for therapeutic applications in advanced multiple myeloma and other neoplasias

PURPOSE: Bortezomib is an important agent in multiple myeloma treatment, but resistance in cell lines and patients has been described. The main mechanisms of resistance described in cancer fall into one of two categories, pharmacokinetic resistance (PK), e.g. over expression of drug efflux pumps and...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Cancer Chemother Pharmacol
Asıl Yazarlar: O’Connor, Robert, Ooi, Melissa G., Meiller, Justine, Jakubikova, Jana, Klippel, Steffen, Delmore, Jake, Richardson, Paul, Anderson, Kenneth, Clynes, Martin, Mitsiades, Constantine S., O’Gorman, Peter
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2013
Konular:
Article
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC4414393/
https://ncbi.nlm.nih.gov/pubmed/23589314
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-013-2136-7
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller